Schrodinger/$SDGR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Schrodinger

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Ticker

$SDGR
Sector
Primary listing

Employees

891

Schrodinger Metrics

BasicAdvanced
$1.4B
-
-$2.48
1.68
-

What the Analysts think about Schrodinger

Analyst ratings (Buy, Hold, Sell) for Schrodinger stock.

Bulls say / Bears say

Total revenue rose 63% year-over-year to $59.6 million in Q1 2025, driven by 46% software growth and 237% drug discovery expansion (Business Wire)
Maintained 2025 financial guidance with software revenue growth of 10–15% and drug discovery revenue of $45–50 million, reflecting management confidence in the business model (Business Wire)
Cash and marketable securities increased to $512 million at the end of Q1 2025, strengthening the balance sheet and funding runway for R&D and strategic initiatives (Business Wire)
Net loss widened to $59.8 million in Q1 2025 from $54.7 million a year earlier, underscoring continued unprofitability despite revenue growth (Business Wire)
Software gross margin fell to 72% in Q1 2025 from 76% in Q1 2024, driven by higher costs associated with the predictive toxicology initiative, pressuring profitability (Business Wire)
Q1 2025 drug discovery revenue included $5.7 million of amortized upfront payment from Novartis, highlighting variability and dependence on large collaboration milestones (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Schrodinger Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Schrodinger Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SDGR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs